Skip to main content
. 2020 Sep 3;14(1):299–309. doi: 10.1111/cts.12868

Figure 1.

Figure 1

Mean ALT, AST, GGT, alkaline phosphatase and total bilirubin values in Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON). Mean (± SEM) ALT, AST, GGT, alkaline phosphatase, and total bilirubin values (U/L) for patients randomized to bardoxolone methyl (n = 1,088) or placebo (n = 1,097) through 48 weeks of treatment. Post‐treatment values collected 4 weeks after the last dose of study drug was administered are also shown. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase.